Compare FirstEnergy Corp. (FE) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FirstEnergy Corp. vs Vertex Pharmaceuticals Incorporated — how do they compare? FirstEnergy Corp. trades at $44.87 (market cap $25.95B), while Vertex Pharmaceuticals Incorporated trades at $508.92 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 4.9× FirstEnergy Corp.'s market cap, and FirstEnergy Corp. pays a 4.15% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold FirstEnergy Corp. for 71 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| FE | VRTX | |
|---|---|---|
Market Cap | $25.95B | $127.55B |
Volume | 5,643,833 | 1,487,944 |
Sector | Utilities | Health |
52-Week High | $51.91 | $557.96 |
52-Week Low | $43.04 | $407.37 |
Typical Hold Time | 71 Days | 120 Days |
Enterprise Value | $54.87B | $121.68B |
Dividend Yield | 4.15% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FirstEnergy (FE) trades at $44.58, up 0.72% with a bullish technical signal despite mixed earnings. The utility shows steady revenue growth to $15.09B in 2025 and maintains a 6.86% net margin, though recent quarters saw two EPS misses. Analyst consensus is Moderate Buy with a $52.80 target, while institutional interest grows with recent purchases by Nykredit and Corient Private Wealth.
FE offers stable utility operations with dividend support, but faces execution risks from its $36B Energize365 plan and rising debt. The stock's 8.4% upside to target and 4.2% dividend yield appeal to income investors, though high RSI suggests near-term pressure. Regulatory approvals and data-center demand are key catalysts.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong fundamentals with $12B revenue, 35% net margin, and robust cash flow. Recent positive Phase 2b data for kidney drug inaxaplin and cystic fibrosis dominance support growth. Earnings show volatility with Q1 beat but Q2 miss against expectations.
Outlook remains positive with 84% analyst buy ratings and $573.50 consensus target offering 13% upside. Key risks include clinical trial outcomes, competitive pressures, and reliance on cystic fibrosis portfolio. The stock presents growth potential through pipeline expansion but faces sector volatility and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About FirstEnergy Corp.
FirstEnergy is one of the largest investor-owned utilities in the United States with 10 regulated distribution companies across six mid-Atlantic and Midwestern states. FirstEnergy also owns and operates one of the nation's largest electric transmission systems with 24,000 miles of lines.
Read more on FE →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
